海王生物：公司累计担保余额约为人民币45.09亿元

Group 1 - The core point of the article is that Haiwang Bio has announced its cumulative guarantee balance of approximately RMB 4.509 billion, which accounts for 158.55% of the company's audited net assets for the fiscal year 2024, with no overdue guarantees reported [1] - For the first half of 2025, the revenue composition of Haiwang Bio is as follows: pharmaceutical commercial circulation accounts for 62.16%, medical device circulation accounts for 34.84%, pharmaceutical manufacturing accounts for 1.96%, health products and food account for 0.58%, and other businesses account for 0.46% [1] - As of the report date, Haiwang Bio has a market capitalization of RMB 9.5 billion [1]